

# Trial Nation

Clinical Trials Denmark

## Danish National Molecular Tumor Board

---

# Danish National Molecular Tumor Board

---

The Danish National Molecular Tumor Board (DNMTB) arose out of the tumor board established at Rigshospitalet in 2013. Since 2019, the function has been nationwide with weekly meetings.

Within the field of precision medicine/personalized medicine across specialties, and malignant as well as non-malignant diagnoses, DNMTB is, by far, the most well-organized and largest forum in Denmark, both in terms of the number of participants, the complexity of the analyses, the number of diagnoses and number of analyzes processed over time. Currently, DNMTB reviews more than 1700 cases annually.

## Purpose

---

- To function as a multidisciplinary, national body for the interpretation of molecular biology studies (comprehensive genomic profiling, whole genome sequencing, etc.) performed on patients with widespread cancer, including continued development and streamlining of work processes.
- To guide experimental treatment and facilitate the allocation of patients to clinical trials on the basis of the aforementioned molecular biological studies.
- To develop national guidelines for the multidisciplinary management of patients' comprehensive genomic studies in relation to interpretation, treatment recommendations and facilitation for drug trials.
- To support the pre- and postgraduate education in relation to interpretation and patient-related implementation of data generated by comprehensive genomic profiling.
- To work for national standards for the interpretation and subsequent clinical use of molecular biology data.
- To work for the implementation of oncological precision medicine as an independent specialist area within the DMCG structure.
- To support the development of multidisciplinary forums for the implementation of precision medicine outside the oncology specialty, e.g. in continuation of the 17 selected patient groups by the National Genome Center (<https://ngc.dk/sundhedsfaglige/patientgrupper>).
- To establish clinical databases, quality databases and clinical trial manager solutions nationally.
- To work for the implementation of machine learning/AI models for the interpretation and implementation of complex molecular biological data.

## Patients

---

The DNMTB is a powerful instrument in relation to the identification of relevant patients with molecular changes for specific drug trials.

As such, the number of discussed and presented molecular biological profiles has steadily increased over the years, with approximately 30/week in the first half of 2022. Today all Danish oncology clinics are covered by the board. It is estimated that over 200 patients are annually allocated to phase 1, 2 and 3 trials, with most patients allocated to commercial phase 1 and 2 trials.

Referral of patients between clinics is a natural consequence of work.

DNMTB serve as competent authority for determining molecular eligibility of genomic alterations to targeted therapy in the Protarget trial ([www.protarget.dk](http://www.protarget.dk)).

## Looking to the future

---

Many future drug trials and treatments will likely be based on extensive molecular biology studies.

Spreading the DNMTB structure and the intended development projects (clinical trial manager, AI models, national standards) to other specialties will help other specialties to attract drug trials to the country and more effectively provide treatment options for patients.

## Organization and representation

---

DNMTB is an independent board based on a steering group of 17 people appointed by the department heads from clinical and diagnostic departments as well as select scientific societies covering all the Danish regions.

| HOSPITAL                              | DEPARTMENT                 | NAME                     |
|---------------------------------------|----------------------------|--------------------------|
| Danish Society for Clinical Academics |                            | Dorthe Ørnskov           |
| Danish Society of Medical Genetics    |                            | Karin Wadt               |
| Herlev Hospital                       | Oncology                   | Rikke Eefsen             |
| Herlev Hospital                       | Pathology                  | Estrid Høgdall           |
| Odense University Hospital            | Pathology                  | Maria Lyng               |
| Odense University Hospital            | Oncology                   | Annette Raskov Kodahl    |
| Regional Hospital, Goedstrup          | Oncology                   | Trine Øllegaard          |
| Rigshospitalet                        | Oncology, The Phase I Unit | Martin Hoejgaard (Chair) |
| Rigshospitalet                        | Genomic Medicine           | Christina Westmose Yde   |
| Vejle Hospital                        | Oncology                   | Marianne Ingerslev Holt  |
| Vejle Hospital                        | Clinical Pathology         | Sanne Kjær-Frifeldt      |
| Zealand University Hospital           | Oncology                   | Lise Søndergaard         |
| Zealand University Hospital           | Pathology                  | Maria Kefala             |
| Aalborg Universitetshospital          | Oncology                   | Morten Ladekarl          |

|                              |                       |                                    |
|------------------------------|-----------------------|------------------------------------|
| Aalborg Universitetshospital | Molecular Diagnostics | Inge Søkilde Pedersen              |
| Aarhus University Hospital   | Molecular Medicine    | Søren Vang                         |
| Aarhus University Hospital   | Oncology              | Britt Elmedal Laursen (Vice-Chair) |

Currently, DNMTB has not received grants, the operation is based on voluntary work from the departments and individuals involved. The long-term ambition is to obtain external grants and/or public funding, etc. to be able to develop DNMTB cf. the above purpose description.

## Contact

---

For a coordinated request to DNMTB, please contact:

- Chair Martin Hoejgaard, [martin.hoejgaard@regionh.dk](mailto:martin.hoejgaard@regionh.dk) from Rigshospitalet
- Vice-Chair Britt Elmedal Laursen, [britla@rm.dk](mailto:britla@rm.dk) from Aarhus University Hospital

Trial Nations facilitator for Molecular Boards: Ask Aabenhus, [aaa@trialnation.dk](mailto:aaa@trialnation.dk)

# Trial Nation

**Get in touch**

[www.trialnation.dk](http://www.trialnation.dk)

[contact@trialnation.dk](mailto:contact@trialnation.dk)

+45 20 22 42 38